A new study explores PET-guided risk stratification to tailor salvage therapy in pediatric relapsed/refractory Hodgkin ...

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

A recent retrospective study has shed new light on the effectiveness of chimeric antigen receptor T cell therapy for patients ...

An inspirational 14-year-old who used her cancer diagnosis as a springboard to support other young patients, has been recognised by HRH The Duke ...

Navi Mumbai: In a medical breakthrough at Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai, a 39-year-old Rijesh Nair, a ...

A 19-year-old has shared the pre-cancer symptoms he noticed prior to being diagnosed with with stage four Hodgkin lymphoma.

Follicular lymphoma is considered an indolent disease, with long-term tumour control achieved by first-line ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

Axicabtagene ciloleucel had durable responses, long-term survival, and consistent outcomes in patients with relapsed or ...

Georgie Swallow was just 28-years-old when she received the devastating news that she had stage 4 Hodgkin lymphoma ...